References
- Ferrajoli A, Faderl S, Ravandi F, Estrov Z. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 2006;6:671–679.
- James C, Ugo V, Le Couedic JP, et al A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–1148.
- Baxter EJ, Scott LM, Campbell PJ, et al Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
- Kratz CP, Boll S, Kontny U, Schrappe M, Niemeyer CM, Stanulla M. Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 2006;20:381–383.
- Lee JW, Kim YG, Soung YH, et al The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006;25:1434–1436.
- Zhang SJ, Li JY, Li WD, Song JH, Xu W, Qiu HX. The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient. Clin Lab Haematol 2007;29:71–72.
- Schnittger S, Bacher U, Kern W, Schroder M, Haferlach T, Schoch C. Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 2006;20:2195–2197.
- Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008;111:2785–2789.
- Barragan E, Collado M, Cervera J, et al The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leuk Res 2007;3:947–953.
- Büchner T, Hiddemann W, Wormann B, et al Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999;93:4116–4124.
- Bolaños-Meade J, Guo C, Gojo I, Karp JE. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML. Leuk Rese 2004;28:571–577.
- Fagerlund TH, Braaten O. No pain relief from codeine? An introduction to pharmacogenomics. Acta Anaesthesiol Scand 2001;45:140–149.
- Rothenberg ML, Meropol NJ, Poplin EA, van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801–3807.
- Pardanani A, Lasho TL, Finke CM, et al The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia 2010;24:110–114.
- Jones AV, Chase A, Silver RT, et al JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009;41:446–449.
- Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma 2008;49:388–397.
- Sarolta N, Hajnalka A, Zoltan M, Nora L, Sandor L, Tamas M. Clinical characteristics of JAK2 V617F mutation positive acute myeloid leukemia. Blood 2006;108(Suppl. 1): (Abstract 4508).